Member Info for OAPK20

For each £100,000 drawdown E3 Fund would need to flip

4,761,905 shares if volume is there

No thanks. Look at PHC.

A good time for a drawdown. In part or in full up to £500,000 at price of 2.1p.

Just remember current funding position.

I know it’s a sideshow but it’s a bit of positive news which will hopefully see an increase in Put option value as CDT make progress. (Yes I know too if CIZ haven’t sold them at a massive loss etc etc 😜)

Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced the appointment of Dr. Joanne Holland as Chief Scientific Officer.

Dr. Holland brings over 20 years of experience to the CSO role at Conduit, having amassed expertise across the entire development spectrum. This includes a deep knowledge base in identifying drugs that can be applied across multiple disease states, combining research and commercial skills to advance drugs to market, and working with premier scientific thought leaders. She has a specific focus in solid-form technology and its associated intellectual property, having held leadership positions at publicly traded companies in this space, as well as consulting roles for several pharmaceutical companies on all matters relating to solid-form technology. She has successfully shepherded multiple solid-form candidates from discovery stage into the clinic, and is the author of over 50 solid-form intellectual property patents. Dr. Holland earned a PhD in chemistry from the University of Leeds, UK, which was sponsored by Pfizer, Inc., before starting her career at companies including Millennium Pharmaceuticals and Stylacats Limited.

In addition, Conduit has engaged Dr. Jeff Lindeman to consult on intellectual property strategies as part of the Company’s research and development of its solid-form candidates. An international speaker, Dr. Lindeman has authored book chapters on patent strategies relating to pharmaceutical solid-state forms. Prior to opening his consulting firm Two Notch Solutions, LLC, in 2009, Dr. Lindeman founded and then successfully sold J.A. Lindeman & Co. PLLC (now Raphael Bellum PLLC) and has over 30 years of intellectual property law experience, including as an adjunct patent law professor at American University and as a United States patent examiner. His role with the Company is as a consultant, not legal counsel.

“The appointment of Jo as Chief Scientific Officer underscores Conduit’s commitment to optimizing the value of our current intellectual property assets, while concurrently fostering the creation of new intellectual property,” said Dr. David Tapolczay, Chief Executive Officer. “Jo and Jeff have over 20 years of experience working together, and their new leadership roles will significantly enhance our intellectual property state, strategically positioning Conduit for future out-licensing opportunities.”

Ticking up on small trades. Hope the drip selling doesn’t start again to peg any rise back

A reply to the Governor of Texas comment.

Proud to sign a Statement of Mutual Cooperation with Secretary Kemi Badenoch today in London to deepen the strong economic relationship between Texas and the U.K.

Reply

“Awesome news! We are currently opening a new company in San Antonio with exciting technology coming out of the UK, would love to explain how this partnership will save many lives!”

Foreign Application Priority Data - not sure if this means it’s a priority application for grant. (If it is 12months nearly up)

Exciting to read

Treating

[0172] In one aspect the present invention relates to a method for treating a subject with cancer comprising administering to the subject a cancer therapeutic; wherein the subject has been identified as having cancer by a method of the present invention.

[0173] In another aspect the present invention provides an anticancer drug for use in treating cancer wherein the subject has been identified as having cancer by a method of the present invention. In a further aspect, the present invention relates to an anticancer lung cancer drug for use in treating lung cancer wherein the subject has been identified as having lung cancer by a method of the present invention.

Anticancer Drug

[0175]

An ‘anticancer drug’ is synonymous with a cancer therapeutic and refers to an entity which may be used to treat cancer.

0176]

The anti-cancer drug may be a cytokine or haematopoietic factor including, but not limited to, IL-1, IL-2, IL-4, IL-5, IL-13, IL-6, CSF-1, M-CSF, GM-CSF, IFNα, IFNβ, IFNγ, IL-10, IL-12, VEGF, bone morphogenic proteins, FGFs, TNF and TGFβ.

0178]

The anticancer drug may be a siRNA or shRNA.

[0179]

Suitably, the anticancer drug may be an anticancer lung cancer drug. An anticancer lung cancer drug refers to an entity which may be used to treat lung cancer.

See it the trades tomorrow track CDT movement

395,460 X 3.1

Would much rather 395,460 x 10

According to company forecast they need not less than £1M additional funding. (£0.5M to fund the corporate and operational overheads of the business and £0.5M for the future additional development of projects.)

Drawdown in full covers half.

Also no update re outsourcing future manufacturing process to a partner specialising in manufacture?

There are a lot of questions and currently nothing from the CEO.

Other than options does the CEO hold any shares ?

.

Which is what I said

CDT had shown a rise into this morning. There was buying here this morning. CDT dropped pre market and at open and there was a sell off here.

Chasing CDT here that’s all. Still pointless.

Well that was pointless

Ticks both boxes

If it’s at his home then I would suggest it’s set up for tax purposes. Nothing more exciting

https://www.irs.gov/newsroom/how-small-business-owners-can-deduct-their-home-office-from-their-taxes

7 months on. Will they RNS the commencement production and clinical trials or is it going to be results of clinical trial and move to commercial production?

After patent grant or not?

“The next steps are to finalise standard production and operating protocols and to commence clinical trials that should lead to an accredited Laboratory Developed (LDT) test for launch initially in the USA. “

I did Tech but the opposing view here seems to have been they would sell CDT shares at a massive loss rather than use the drawdown facility.

I still think the option to use the drawdown is the preferred option.

This the one ?

Cizzle Bio Inc.

Company Number

0805434362

Company Type

Domestic For-Profit Corporation

Jurisdiction

Texas (US)

Registered Address

1 CHARTERWOOD

SAN ANTONIO

78248-1660

TX

USA

Alternative Names

Cizzle Bio Inc. (trading name, 2024-02-25 - )

Agent Name

William Behnke

Agent Address

1 Charterwood, San Antonio, TX, 78248, USA